Floatz logo

Tariquidar

Renal Neoplasms

National Cancer Institute (NCI)Small moleculePhase 2Dormant
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
39/ 100
Competitive Position
95/ 100

Competitive context

17 Active assets in the Renal Neoplasms cohort.

Asset / SponsorPhaseRating
Axitinib
Pfizer
Phase 3BB
Ipilimumab
Pfizer
Phase 4BB
Nivolumab
Bristol-Myers Squibb
Phase 4BB
Inno-206
Merck Sharp & Dohme LLC
Phase 2BB
Sorafenib
Pfizer
Phase 3B

View all 50 →

Same molecule, other indications

Tariquidar is also rated in:

non-small cell lung carcinomaDormant
B
Indicative ·
56 / 100
View asset →
cervical cancerDormant
CCC
Indicative ·
54 / 100
View asset →
lung neoplasmDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →